+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
53.9900
3.2507
3.2507
.0466
4.7894
20.8989
High
87.0258
4.0641
No
Yes
No
No
Yes
No
0.0
No
Yes
Yes
Yes
Kadsurenone is a natural lignan compound derived from the stem of the traditional Chinese medicinal herb Piper kadsura, attracting attention for its specific antagonistic activity against platelet-activating factor (PAF). Platelet activating factor, as a potent bioactive lipid mediator, participates in various physiological and pathological processes, including inflammatory responses, blood coagulation, allergic reactions, and immune regulation. In recent years, with in-depth research into the mechanisms of inflammation-related diseases, Haifeng Tengone has demonstrated unique pharmacological potential in the field of anti-inflammation.
This paper will systematically review the chemical structure and physicochemical properties of Haifeng Tengketone, its plant origin, and extraction methods, focusing on its pharmacological activity and mechanism of action, exploring its druggability parameters and pharmacokinetic characteristics, and looking ahead to its potential value and development prospects in clinical applications, aiming to provide theoretical basis and research directions for the pharmacology of natural products and new drug development.
The molecular formula of Haifeng Tengone is C21H24O5, with a molecular weight of 356.4180. Its chemical structure belongs to the lignan compounds, featuring a typical diphenylpropane backbone. The structure contains multiple hydroxyl and methoxy substituents, giving it certain polarity and biological activity. According to existing literature, Haifeng Tengone has a LogP value of 3.2507, indicating moderate lipid solubility, which facilitates cell membrane penetration and distribution in vivo.
The polar surface area (TPSA) was 53.99 Ų, indicating a moderate level of molecular polarity, which facilitates binding to biological macromolecule targets. Low water solubility (0.0466 mg/mL) suggests limited solubility in the aqueous phase, which may affect oral bioavailability. Notably, Haifeng Tengone has a high blood-brain barrier penetration ability, providing a theoretical basis for its application in central nervous system diseases. Additionally, Haifengtengone does not exhibit hERG channel inhibitory activity, and Ames mutagenic test results are negative, indicating high safety and reduced risks of cardiotoxicity and genotoxicity.
Haifeng Tengone mainly comes from the stem of the Haifeng vine (Piper kadsura) plant. Piper kadsura is a perennial woody vine distributed in East Asia, commonly used in traditional Chinese medicine to treat rheumatic pain, bruises, and inflammation-related diseases. The stems are rich in lignan compounds, with Haifeng Tengone being one of its main active ingredients and exhibiting significant biological activity.
Common methods for extracting Haifeng Tenketone include solvent extraction, column chromatography separation, and high-performance liquid chromatography (HPLC) purification. Ethanol or methanol is typically used as extraction solvents, and extraction efficiency is improved through reflux or ultrasound-assisted extraction. After concentration, the extract was separated by silica gel column chromatography, combined with thin-layer chromatography (TLC) to monitor the target components, and then purified by reversed-phase HPLC to obtain high-purity Haifengtengone. In recent years, supercritical CO2 extraction technology has also been attempted to extract Haifeng Tengketone, offering advantages such as high extraction efficiency and environmental friendliness.
Research on the pharmacological activity of Haifengtengone mainly focuses on its anti-inflammatory effects and the antagonistic activity of platelet-activating factor. As a specific PAF antagonist, Haifeng Tengketone can effectively inhibit PAF-mediated platelet aggregation and inflammatory responses, demonstrating potential antithrombotic and anti-inflammatory effects.
Multiple in vitro and in vivo experiments have shown that Haifeng Tengone can significantly inhibit the production and release of inflammatory mediators. For example, in macrophage and monocyte models, Haifengtengone inhibited the expression of pro-inflammatory cytokines such as IL-6 and TNF-α, reducing the inflammatory cascade of cytokines. Additionally, Haifeng Tengone regulates inflammation-related enzymes such as cyclooxygenase (COX-1/PTGS1, COX-2/PTGS2) and induced nitric oxide synthase (NOS2), reducing the generation of inflammatory mediators.
The regulatory effect of Haofengtengone on TRPV1 and TRPA1 channels provides a basis for its application in neuroinflammation and pain management. TRPV1 and TRPA1 are important ion channels for sensing pain and inflammatory stimuli. Haifengtengone alleviates neuroinflammation and related pain symptoms by modulating these targets.
The regulatory effects of Haifeng Tengone on inflammation-related signaling pathways such as STAT3 and NF-κB have also been widely reported. By inhibiting the activation of STAT3 and NF-κB, Haifengtengone reduces the transcription of inflammatory genes and suppresses the persistence and spread of inflammatory responses. Additionally, the effect of Haifengtengone on the inflammasome-related protein CASP1 suggests it may be involved in regulating the apoptosis (pyroptosis) process of inflammatory cells.
The pharmacological mechanism of Haifengtengone mainly relies on its regulation of various inflammation-related molecular targets, specifically including:
Platelet-activating factor (PAF) receptor antagonism: As a specific antagonist of PAF, Haifeng Tengone blocks PAF binding to its receptors, inhibits PAF-mediated platelet aggregation and inflammatory signaling, and reduces thrombosis and inflammatory responses.
Cytokine regulation: Haikazetenone inhibits the expression of pro-inflammatory cytokines such as IL-6 and TNF-α, reducing inflammatory responses in immune cells.
Regulation of signaling pathways: By inhibiting the STAT3 and NF-κB signaling pathways, Haifengtengone blocks the transcriptional activation of inflammation-related genes, reducing the production of inflammatory factors.
Regulation of enzyme activity: Regulate the expression and activity of key inflammatory enzymes such as PTGS1, PTGS2, and NOS2, reducing the production of inflammatory mediators like prostaglandins and nitric oxide.
Ion channel regulation: Haifeng Tengone inhibits TRPV1 and TRPA1 channels, helping to relieve neuroinflammation and pain.
Inflammationsome regulation: By influencing CASP1 activity, Haifengtengone may regulate inflammasome-mediated apoptosis and inflammatory responses.
Overall, Haifengtengone exerts significant anti-inflammatory and antithrombotic activity through its multi-target and multi-pathway synergistic effects, demonstrating the advantages of multi-target pharmacology as a natural product.
The druggability parameters of Haifengtengone indicate that it has promising potential for drug development. Its molecular weight (356.4180) complies with the Lipinski rule, and the LogP value (3.2507) is moderate, indicating good membrane permeability and in vivo distribution capability. TPSA was 53.99 Ų, below the threshold of 140 Ų, indicating it may have good oral absorption.
Low water solubility (0.0466 mg/mL) may limit its oral bioavailability and requires formulation optimization or structural modification. High blood-brain barrier permeability offers potential applications in central nervous system diseases. In terms of safety, Haifengtengone does not inhibit hERG channels, reducing the risk of cardiotoxicity; A negative Ames test indicates a low genotoxicity risk.
Currently, pharmacokinetic research on Haifengtengone is relatively limited. Preliminary data indicate good stability and distribution characteristics in vivo, but its metabolic pathways and clearance mechanisms still require further elucidation. Future research should focus on its in vivo metabolic kinetics, oral bioavailability, and potential drug interactions to guide clinical development.
Based on Haifeng Tengone's excellent anti-inflammatory activity and good safety, its clinical application prospects in various inflammation-related diseases are broad in the future. Specifically, it includes:
Rheumatic immune diseases: such as rheumatoid arthritis and systemic lupus erythematosus. Haefeng Tengone is expected to alleviate joint inflammation and tissue damage by inhibiting inflammatory factors and signaling pathways.
Neuroinflammation and pain management: Its regulatory effect on TRPV1/TRPA1 provides new therapeutic strategies for chronic pain and neuropathic pain.
Cardiovascular Diseases: By blocking PAF-mediated platelet aggregation, Haefengtengone may prevent thrombosis and reduce the risk of cardiovascular events.
Tumor-related inflammation: Due to the important roles of STAT3 and NF-κB pathways in the tumor microenvironment, the multi-target regulatory ability of Haifengtengone offers potential support for anti-tumor inflammation.
Future clinical research needs to systematically evaluate the pharmacodynamics, safety, and dosage optimization of Haifengtengone, combined with modern drug formulation technologies to enhance its bioavailability and targeting. At the same time, due to its multi-target characteristics, Haifeng Tengketone can serve as a candidate molecule for combination therapy, exerting synergistic effects in the treatment of complex diseases.
Haifeng Tengone is a natural lignan with specific platelet-activating factor antagonistic activity, demonstrating significant anti-inflammatory, antithrombotic, and neuroprotective effects. Its multi-target regulatory mechanism and favorable druggability parameters have laid a solid foundation for its new drug development. Although research on its pharmacokinetics and clinical applications is still in its early stages, Haifeng Tengone remains a model for pharmacological research of natural products and holds broad application prospects.
Future research should focus on deeply elucidating its molecular mechanisms, optimizing extraction and formulation processes, conducting systematic pharmacokinetic and toxicological evaluations, and promoting the development of preclinical and clinical trials. Through multidisciplinary collaboration, Haifengtengone is expected to become an important drug candidate in the field of anti-inflammatory and related disease treatments, promoting innovative development in natural product pharmacology.
Shenshuai
Wenjing
Hedandan
